Enzyme inhibitors block replication of SARS virus

The study was conducted by researchers from Scripps Research; the Genomics Research Center, Academia Sinica, Taiwan; and the National Taiwan University. It is being published today in the journal Chemistry and Biology.

Chi-Huey Wong is currently the Ernest W. Hahn Chair in Chemistry at the Skaggs Institute of Chemical Biology and directs the Scripps Research lab heading the study. He said the new finding is an important step in developing a possible drug treatment against SARS.

"We have been working on the problem of SARS since the epidemic started in 2003," Wong said. "This new class of inhibitors represents the most potent SARS virus protease inhibitors known today."

The path to today's research finding has taken several years. In 2002, Severe Acute Respiratory Syndrome (SARS) emerged in rural China and eventually spread to 32 countries, according to the World Health Organization. SARS is caused by a ring-shaped virus, known as a coronavirus. The SARS coronavirus is suspected of originating in animal populations before migrating to humans. Hardest-hit were six Asian nations. By the time the epidemic had been controlled in 2003, the disease infected more than 8,000 people, causing 800 deaths. There is no current effective treatment or vaccine.

Researchers have known since 2003 that a site on the virus is responsible for mediating proteases that allow the virus to replicate. Since then researchers have been testing protease inhibitors to lock up this site, known as SARS 3CLpro, and effectively stop the virus from infecting additional cells in the body.

In 2004, Wong's lab discovered that Lopinavir, a protease inhibitor of HIV also known as TL3, also served as weak inhibitor of the SARS 3CLpro site (PNAS, 101, 10012-10017). Since then, members of Wong's group further studied Lopinavir and are preparing it for clinical trials against SARS.

Researchers in Wong's lab at Scripps Research and in Taiwan have been looking at other Liponavir-related compounds for similar blocking effects. During these experiments, they found that a group of catalyzing agents used to help promote chemical reactions in the laboratory were actually more powerful in blocking the SARS protease than either the Lopinavir or any of the target compounds.

These organic compounds are called benzotriazole esters. The esters entered the SARS protease site, formed an intermediary compound, then inactivated the SARS enzyme. The findings were confirmed using mass spectrometry analysis of the enzyme intermediary.

"These benzotriazole esters are relatively stable and act as suicide inhibitors," Wong said. "They block the enzyme, are transformed through a co-valent bond, and are unable to get out."

Wong said the findings published today provide better insight into the mode of action of the enzyme, which may lead to development of a drug against SARS. The findings were made by using rapid drug discovery techniques developed in the Wong lab to screen large numbers of weak enzyme inhibitors, and then attaching additional compounds to look for stronger reactions.

Research Associate Chung-Yi Wu, a member of the Wong lab, is the paper's lead author. He said the finding was unexpected.

"We wanted to improve Liponavir activity," Wu said. "But we found this very surprising and serendipitous result."

Source: Scripps Research Institute

Related stories:

Human antibodies that block human and animal SARS viruses identified
An international team of investigators has identified the first human antibodies that can neutralize different strains of the virus responsible for outbreaks of severe acute respiratory syndrome (SARS).
Researchers gain traction in race against pandemics
Is another pandemic on the scale of the 1918 influenza pandemic inevitable, or can research and prevention head off another deadly transmission of animal viruses to human populations?
Research leads to first treatment for drug-resistant HIV
Doctors have their first FDA-approved tool to treat drug-resistant HIV thanks to a new molecule created by a Purdue University researcher.
Novel drug for SARS shows promise
A prototype drug created by researchers at the University of Illinois at Chicago shows promise in slowing replication of the virus responsible for severe acute respiratory syndrome, or SARS.
Currently, there are no effective antiviral agents or vaccines for SARS, which killed almost 800 people in an epidemic in 2002-2003.
Skype admits privacy breach by Chinese partner (Update)
Skype on Thursday became the latest US firm embroiled in controversy over its operations in China, acknowledging that its Chinese partner had been archiving politically sensitive text messages.
Capturing replication strategies used by SARS viruses in their bid to spread
Just over five years ago, an outbreak of severe acute respiratory syndrome (SARS)-coronavirus killed over 750 people. SARS (corona)virus, a positive-stranded RNA virus, replicates in the cytoplasm of host cells, attaching its replication complex to intracellular membranes that it has modified for this purpose.
Researchers identify virus behind mysterious parrot disease
Researchers at the University of California, San Francisco, have identified a virus behind the mysterious infectious disease that has been killing parrots and exotic birds for more than 30 years.
Scientists break record by finding northernmost hydrothermal vent field
Well inside the Arctic Circle, scientists have found black smoker vents farther north than anyone has ever seen before. The cluster of five vents – one towering nearly four stories in height – are venting water as hot as 570 F.

News discussion:

General Science news